Online inquiry

IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9950MR)

This product GTTS-WQ9950MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9950MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14100MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ11548MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ4442MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ15476MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ7811MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ11201MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ15346MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ7413MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW